- ICH GCP
- US Clinical Trials Registry
- Clinical Trial NCT01695447
Duct-to-mucosa Versus Invagination for Pancreaticojejunostomy
January 25, 2017 updated by: TingBo Liang
Randomised Controlled Trail of Duct-to-mucosa Versus Invagination for Pancreaticojejunostomy After Pancreaticoduodenectomy
The purpose of this study is to determine whether duct-to-mucosa is better than invagination in pancreaticojejunostomy after pancreaticoduodenectomy.
This single-centre, open, randomized controlled trail is conducted following ISGPF criteria for pancreatic fistula (PF).
The duration of the study is supposed to start from Jan 5th 2012 and last to Dec 2014, until 100 or more cases are accessible.
Patients diagnosed with pancreatic cancer, peri-ampullar carcinoma or other benign or malignant diseases which need to operate pancreaticoduodenectomy will be included.
Main outcomes are pancreatic fistula rate, mortality, morbidity, reoperation and hospital stay.
The investigators assumption that duct-to-mucosa is better than invagination.
Study Overview
Status
Unknown
Conditions
Intervention / Treatment
Study Type
Interventional
Enrollment (Anticipated)
100
Phase
- Not Applicable
Contacts and Locations
This section provides the contact details for those conducting the study, and information on where this study is being conducted.
Study Contact
- Name: Xue-Li Bai, Ph.D.
- Phone Number: +86 571 87783510
- Email: shirleybai57@hotmail.com
Study Locations
-
-
Zhejiang
-
Hangzhou, Zhejiang, China, 310009
- Recruiting
- the Second Affiliated Hospital, School of Medicine, Zhejiang Universtiy
-
Contact:
- Ting-Bo Liang, Ph.D., M.D.
- Phone Number: +86 571 87783510
- Email: liangtingbo@zju.edu.cn
-
-
Participation Criteria
Researchers look for people who fit a certain description, called eligibility criteria. Some examples of these criteria are a person's general health condition or prior treatments.
Eligibility Criteria
Ages Eligible for Study
18 years to 80 years (Adult, Older Adult)
Accepts Healthy Volunteers
No
Genders Eligible for Study
All
Description
Inclusion Criteria:
- Patients diagnosed with pancreatic cancer or other diseases which need pancreaticoduodenectomy and pancreaticojejunostomy
- 18 to 80 y/o
- Operation-tolerated
- Informed consent
Exclusion Criteria:
- History of gastrointestinal operation
- Pancreaticoduodenectomy is given up during operation
- Pancreatic duct is difficult to locate
- Patients require to exit from the study anytime
Study Plan
This section provides details of the study plan, including how the study is designed and what the study is measuring.
How is the study designed?
Design Details
- Primary Purpose: Treatment
- Allocation: Randomized
- Interventional Model: Parallel Assignment
- Masking: Triple
Arms and Interventions
Participant Group / Arm |
Intervention / Treatment |
---|---|
Experimental: duct-to-mucosa
duct-to-mucosa technique is used for pancreaticojejunostomy after pancreaticoduodenectomy
|
Internal stent may be used during pancreaticojejunostomy according to the situation of pancreatic duct and experience of the surgeon.
|
Active Comparator: invagination
invagination technique is used for pancreaticojejunostomy after pancreaticoduodenectomy
|
Internal stent may be used during pancreaticojejunostomy according to the situation of pancreatic duct and experience of the surgeon.
|
What is the study measuring?
Primary Outcome Measures
Outcome Measure |
Measure Description |
Time Frame |
---|---|---|
pancreatic fistula
Time Frame: From date of operation until the date of dischage or date of death from any cause, whichever came first,, assessed up to 200 days
|
The determine of pancreatic fistula follows the International Study Group on Pancreatic Fistulas (ISGPF) criteria.
|
From date of operation until the date of dischage or date of death from any cause, whichever came first,, assessed up to 200 days
|
Secondary Outcome Measures
Outcome Measure |
Measure Description |
Time Frame |
---|---|---|
Mortality
Time Frame: From date of operation until the date of in-hospital death or death within 30 days after operation, whichever came first, assessed up to 200 days
|
30-day or in-hospital mortality: death from any cause within 30 days after operation or any in-hospital death are considered concerned with the type of pancreaticojejunostomy
|
From date of operation until the date of in-hospital death or death within 30 days after operation, whichever came first, assessed up to 200 days
|
Morbidity
Time Frame: From date of operation until the date of discharge or date of death from any cause, whichever came first, assessed up to 200 days
|
any complications after operation will be recorded.
|
From date of operation until the date of discharge or date of death from any cause, whichever came first, assessed up to 200 days
|
Reoperation
Time Frame: From date of operation until the date of discharge or date of death from any cause, whichever came first, assessed up to 200 days
|
Reasons and times of reoperation are recorded.
The attending doctor will decided Whether reoperation is needed, according to indications and his experience.
|
From date of operation until the date of discharge or date of death from any cause, whichever came first, assessed up to 200 days
|
Hospital stay
Time Frame: From date of operation until the date of discharge or date of death from any cause, whichever came first, assessed up to 200 days
|
Post-operation hospital stay is assessed.
|
From date of operation until the date of discharge or date of death from any cause, whichever came first, assessed up to 200 days
|
Collaborators and Investigators
This is where you will find people and organizations involved with this study.
Sponsor
Publications and helpful links
The person responsible for entering information about the study voluntarily provides these publications. These may be about anything related to the study.
Study record dates
These dates track the progress of study record and summary results submissions to ClinicalTrials.gov. Study records and reported results are reviewed by the National Library of Medicine (NLM) to make sure they meet specific quality control standards before being posted on the public website.
Study Major Dates
Study Start
January 1, 2012
Primary Completion (Anticipated)
December 1, 2017
Study Completion (Anticipated)
December 1, 2017
Study Registration Dates
First Submitted
September 20, 2012
First Submitted That Met QC Criteria
September 27, 2012
First Posted (Estimate)
September 28, 2012
Study Record Updates
Last Update Posted (Estimate)
January 26, 2017
Last Update Submitted That Met QC Criteria
January 25, 2017
Last Verified
January 1, 2017
More Information
Terms related to this study
Additional Relevant MeSH Terms
Other Study ID Numbers
- ZEH-LL-CX-004-02
This information was retrieved directly from the website clinicaltrials.gov without any changes. If you have any requests to change, remove or update your study details, please contact register@clinicaltrials.gov. As soon as a change is implemented on clinicaltrials.gov, this will be updated automatically on our website as well.
Clinical Trials on Pancreatic Neoplasms
-
Sidney Kimmel Cancer Center at Thomas Jefferson...CelgeneWithdrawnPancreatic Ductal Adenocarcinoma | Stage III Pancreatic Cancer | Stage IV Pancreatic Cancer | Stage IIA Pancreatic Cancer | Stage IIB Pancreatic Cancer | Stage IA Pancreatic Cancer | Stage IB Pancreatic CancerUnited States
-
Memorial Sloan Kettering Cancer CenterRecruitingPancreatic Cancer | Pancreatic Cancer Metastatic | Pancreatic Cancer Stage IV | Metastatic Pancreatic Carcinoma | Metastatic Pancreatic Adenocarcinoma | Pancreatic Carcinoma | Metastatic Pancreatic Cancer | Pancreatic Cancer Non-resectable | Metastatic Pancreatic Ductal Adenocarcinoma | Pancreatic Carcinoma... and other conditionsUnited States
-
Case Comprehensive Cancer CenterNational Cancer Institute (NCI)TerminatedPancreatic Adenocarcinoma | Resectable Pancreatic Cancer | Stage III Pancreatic Cancer | Stage IIA Pancreatic Cancer | Stage IIB Pancreatic Cancer | Stage IA Pancreatic Cancer | Stage IB Pancreatic Cancer | Poorly Differentiated Malignant Neoplasm | Undifferentiated Pancreatic CarcinomaUnited States
-
The First Affiliated Hospital with Nanjing Medical...RecruitingLocally Advanced Pancreatic Adenocarcinoma | Metastatic Pancreatic Cancer | Pancreatic NeoplasmChina
-
Case Comprehensive Cancer CenterNational Cancer Institute (NCI)WithdrawnStage IIA Pancreatic Cancer | Stage IIB Pancreatic Cancer | Stage IA Pancreatic Cancer | Stage IB Pancreatic Cancer
-
National Cancer Institute (NCI)CompletedStage IIA Pancreatic Cancer | Stage IIB Pancreatic Cancer | Stage IA Pancreatic Cancer | Stage IB Pancreatic CancerUnited States
-
University of OxfordNational Institute for Health Research, United Kingdom; ImunonWithdrawnPancreatic Cancer Metastatic | Pancreatic Ductal Adenocarcinoma | Pancreatic Cancer Stage IV | Pancreatic Cancer Non-resectableUnited Kingdom
-
Mayo ClinicNational Cancer Institute (NCI)CompletedAdvanced Pancreatic Carcinoma | Metastatic Pancreatic Carcinoma | Stage II Pancreatic Cancer AJCC v8 | Stage III Pancreatic Cancer AJCC v8 | Stage IV Pancreatic Cancer AJCC v8 | Unresectable Pancreatic Carcinoma | Pancreatic Neoplasm | Locally Advanced Pancreatic CarcinomaUnited States
-
University of UtahNovartis PharmaceuticalsRecruitingMetastatic Pancreatic Carcinoma | Unresectable Pancreatic Carcinoma | Stage III Pancreatic Cancer | Stage IV Pancreatic Cancer | Stage IIA Pancreatic Cancer | Stage IIB Pancreatic Cancer | Stage II Pancreatic CancerUnited States
-
Maria LiljeforsKarolinska University Hospital; Karolinska Institutet; CelgeneCompletedPancreatic Ductal Adenocarcinoma | Pancreatic Carcinoma MetastaticSweden
Clinical Trials on duct-to-mucosa
-
Assiut UniversityNot yet recruiting
-
Chen XiaopingUnknownPancreaticoduodenectomyChina
-
Mansoura UniversityCompletedPancreatic Anastomotic LeakEgypt
-
Nanjing Medical UniversityUnknownPancreatic FistulaChina
-
South Valley UniversityCompleted
-
The University of Hong KongRecruiting
-
University Health Network, TorontoUnknownLiver TransplantationCanada
-
Ochsner Health SystemUnknown
-
Universitaire Ziekenhuizen KU LeuvenCompleted
-
Institute of Biophysics and Cell Engineering of...Belarusian State Medical UniversityCompletedPneumonia, Viral | Pneumonia | Covid-19 | COVID | Coronavirus | Sars-CoV2 | Pneumonia, InterstitialBelarus